Xiaotao Hou
Impact in
- Infectious Diseases top 5%
- COVID-19 Clinical Research Studies
- SARS-CoV-2 and COVID-19 Research
- Pharmacology top 5%
- Pharmacological Effects of Natural Compounds
Papers in
-
- Natural product bioactivities and synthesis 8
- Metabolomics and Mass Spectrometry Studies 6
- Metabolism, Diabetes, and Cancer 4
-
- Phytochemistry and Biological Activities 5
- Co-authors
- Erwei Hao (51 shared papers)Jiagang Deng (49 shared papers)Gang Bai (19 shared papers)Zhengcai Du (27 shared papers)Yuanyuan Hou (11 shared papers)Yueping Liu (1 shared paper)Zeqing Feng (1 shared paper)Liang Liu (1 shared paper)
In The Last Decade
Xiaotao Hou
76 papers receiving 1.3k citations
Xiaotao Hou's Hit Papers
Peers
Comparison fields: 5 of 128
- Infectious Diseases 283
- Pharmacology 102
- Nephrology 77
- Complementary and alternative medicine 90
- Biochemistry 63
Countries citing papers authored by Xiaotao Hou
This map shows the geographic impact of Xiaotao Hou's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xiaotao Hou with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xiaotao Hou more than expected).
Fields of papers citing papers by Xiaotao Hou
This network shows the impact of papers produced by Xiaotao Hou. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xiaotao Hou. The network helps show where Xiaotao Hou may publish in the future.
Co-authors
The 25 scholars most cited alongside Xiaotao Hou, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 81 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Human kidney is a target for novel severe acute respiratory syndrome coronavirus 2 infection Hit paper breakdown → | 2021 | 350 |
| 2 | 2022 | 64 | |
| 3 | 2020 | 48 | |
| 4 | 2020 | 44 | |
| 5 | 2018 | 38 | |
| 6 | 2021 | 30 | |
| 7 | 2021 | 29 | |
| 8 | 2022 | 27 | |
| 9 | 2019 | 27 | |
| 10 | 2020 | 26 | |
| 11 | 2022 | 25 | |
| 12 | 2019 | 24 | |
| 13 | 2021 | 22 | |
| 14 | 2019 | 21 | |
| 15 | 2024 | 20 | |
| 16 | 2020 | 20 | |
| 17 | 2019 | 19 | |
| 18 | 2021 | 19 | |
| 19 | 2020 | 19 | |
| 20 | 2022 | 19 |
About Xiaotao Hou
Xiaotao Hou is a scholar working on Molecular Biology, Plant Science, Oncology, Complementary and alternative medicine and Pathology and Forensic Medicine, having authored 81 papers that have together received 1.4k indexed citations. Recurring topics across this work include Natural product bioactivities and synthesis (8 papers), Metabolomics and Mass Spectrometry Studies (6 papers), Polyomavirus and related diseases (5 papers), Phytochemicals and Antioxidant Activities (5 papers), Phytochemistry and Biological Activities (5 papers), Metabolism, Diabetes, and Cancer (4 papers), Traditional Chinese Medicine Analysis (4 papers) and Pharmacological Effects of Natural Compounds (4 papers). The work is most often cited by research in Infectious Diseases (283 citations), Pharmacology (102 citations), Nephrology (77 citations), Complementary and alternative medicine (90 citations) and Biochemistry (63 citations). Xiaotao Hou has collaborated with scholars based in China, Malaysia and Macao. Frequent co-authors include Erwei Hao, Jiagang Deng, Gang Bai, Zhengcai Du, Yuanyuan Hou, Yueping Liu, Zeqing Feng, Liang Liu, Ji Zhang and Gang Wang. Their work appears in journals such as Journal of Functional Foods, Kidney International Reports, Pharmaceutical Biology, Annals of Translational Medicine and Pharmaceuticals.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.